HC Wainwright Weighs in on Sutro Biopharma Q2 Earnings

Sutro Biopharma, Inc. (NASDAQ:STRO - Free Report) - Research analysts at HC Wainwright issued their Q2 2025 EPS estimates for shares of Sutro Biopharma in a report released on Monday, November 18th. HC Wainwright analyst A. Fein forecasts that the company will post earnings per share of ($0.87) for the quarter. HC Wainwright currently has a "Buy" rating and a $12.00 target price on the stock. The consensus estimate for Sutro Biopharma's current full-year earnings is ($2.89) per share. HC Wainwright also issued estimates for Sutro Biopharma's Q4 2025 earnings at ($0.96) EPS.

Several other research firms have also weighed in on STRO. Piper Sandler reissued an "overweight" rating and issued a $11.00 target price on shares of Sutro Biopharma in a research note on Friday, October 11th. Truist Financial cut their price target on shares of Sutro Biopharma from $18.00 to $15.00 and set a "buy" rating on the stock in a research report on Friday, August 16th. Finally, JMP Securities reissued a "market outperform" rating and issued a $17.00 target price on shares of Sutro Biopharma in a research note on Monday, September 16th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Sutro Biopharma currently has a consensus rating of "Buy" and a consensus price target of $12.14.

Sutro Biopharma Price Performance

Shares of Sutro Biopharma stock traded down $0.05 on Tuesday, hitting $2.70. 2,923,314 shares of the company's stock traded hands, compared to its average volume of 817,481. Sutro Biopharma has a one year low of $2.13 and a one year high of $6.13. The stock has a market capitalization of $222.64 million, a PE ratio of -1.68 and a beta of 1.17. The firm's 50-day moving average price is $3.68 and its two-hundred day moving average price is $3.82.

Institutional Trading of Sutro Biopharma

A number of hedge funds and other institutional investors have recently modified their holdings of STRO. Gladius Capital Management LP acquired a new position in shares of Sutro Biopharma during the 3rd quarter worth approximately $28,000. ProShare Advisors LLC increased its holdings in Sutro Biopharma by 49.1% during the second quarter. ProShare Advisors LLC now owns 16,316 shares of the company's stock worth $48,000 after buying an additional 5,373 shares during the last quarter. Intech Investment Management LLC bought a new stake in shares of Sutro Biopharma in the 3rd quarter valued at about $91,000. Lazard Asset Management LLC acquired a new stake in shares of Sutro Biopharma in the first quarter valued at approximately $92,000. Finally, The Manufacturers Life Insurance Company increased its holdings in shares of Sutro Biopharma by 27.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 32,943 shares of the company's stock worth $97,000 after acquiring an additional 7,082 shares during the last quarter. Institutional investors and hedge funds own 96.99% of the company's stock.

About Sutro Biopharma

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.